Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity.

How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to define cancer morphological diversification within the spatial context of the microenvironment. Tumor spatial zones, where cancer cell nuclei diversify in shape, are mapped in each tumor. Integration of this spatially explicit analysis with omics and clinical data reveals a relationship between morphological diversification and the dysregulation of DNA repair, loss of nuclear integrity, and increased disease mortality. Within the Immunoreactive subtype, spatial analysis further reveals significantly lower lymphocytic infiltration within diversified zones compared with other tumor zones, suggesting that even immune-hot tumors contain cells capable of immune escape. Our findings support a model whereby a subpopulation of morphologically plastic cancer cells with dysregulated DNA repair promotes ovarian cancer progression through positive selection by immune evasion

The role of Cediranib in ovarian cancer.

Introduction Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents. Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent to be incorporated in the ovarian cancer treatment landscape. Other molecules utilising different mechanisms of action to target angiogenesis have been developed, including cediranib, an oral potent inhibitor of VEGF Tyrosine Kinase Inhibitor that has demonstrated activity in both phase II and phase III studies. Areas covered: Herein we will review cediranib as well as the evidence for its use in ovarian cancer, both as monotherapy and in combination with chemotherapy, PARP inhibitors and immunotherapy. A literature search was made in PubMed and on ClinicalTrials.gov for clinical trials with cediranib. Expert opinion: The addition of cediranib for the treatment of ovarian cancer is promising, and has demonstrated a significant improvement in progression free survival in a phase III trial in combination with chemotherapy and maintenance treatment. Cediranib is currently being explored in ovarian cancer and other gynaecological malignancies aiming to improve patient care; further research will help define its role in standard clinical practice for patients with ovarian cancer

Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru

Objective: To determine the time from diagnosis to start of multidrug resistant tuberculosis (MDR TB) treatment in Lima, Peru. Methods: We studied new smear-positive TB adults that were started on MDR TB treatment or that were switched to it between June 2008 and December 2011. Results: Time from the first positive smear to MDR-TB treatment was >30days in 35% (13/37) of patients. Among the 27% (24/88) of patients that switched to MDR-TB treatment, time from the last dose of a drug-susceptible regimen was >30days. Conclusion: Start of and switching to MDR TB treatment is still delayed

Total disc replacement arthroplasty using the AcroFlex lumbar disc: a non-human primate model

Using a non-human primate model, the current study was undertaken to investigate the efficacy of the AcroFlex lumbar disc as an intervertebral disc prosthesis, based on biomechanical, histopathologic and histomorphometric analyses. A total of 20 mature male baboons (Papio cynocephalus, mean weight 30 kg) were randomized into two equal groups based on post-operative time periods of 6 (n=10) and 12 months (n=10). Each animal underwent an anterior transperitoneal surgical approach to the lumbar spine, with intervertebral reconstructions performed at L3-L4 and L5-L6 using the following techniques: (1) tricortical iliac autograft and (2) AcroFlex lumbar disc. The two treatments were equally randomized between the non-contiguous operative lumbar levels. Post-mortem analysis included histopathologic assessment of the systemic reticuloendothelial tissues, multi-directional flexibility testing of the operative functional spinal units and quantitative histological analysis of trabecular bone coverage at the prosthesis endplates. Data were statistically compared using a one-way ANOVA with the Student-Newman-Keuls test. All animals survived the operative procedure and post-operative interval without significant intra- or peri-operative complications. Histopathologic analysis of the paraffin-embedded systemic reticuloendothelial tissues indicated no significant pathologic changes at the 6- or 12-month intervals. Plain film radiographic analysis showed no lucencies or loosening of any prosthetic vertebral endplate. Biomechanical testing of the 6-month autograft, reconstructions with AcroFlex lumbar disc and non-operative control (n=10) intact motion segments indicated no significant differences in peak range of motion (ROM) in axial compression. However, axial rotation produced significantly lower ROM for the autograft treatment compared to the intact and AcroFlex groups (P<0.05). The most significant differences in peak ROM were noted between all treatment groups under flexion/extension and lateral bending loading modalities (P<0.05). By 12 months, the intact condition indicated significantly more motion in all bending modes compared to the AcroFlex and autograft treatments, which were not statistically different from each other (P>0.05). Gross histopathologic analysis of the AcroFlex disc prosthesis demonstrated excellent ingrowth at the level of the implant-bone interface, without evidence of fibrous tissue or synovium. BioQuant histomorphometric analysis at the metal-bone interface (bone contact area/total endplate area) indicated the mean ingrowth was 54.59±13.24% at 6 months and 56.79±5.85% at 12 months. Radiographic analysis showed no lucencies or loosening of the AcroFlex vertebral endplate. Based on multi-directional flexibility testing, motion was preserved in axial rotation, but significantly diminished in the other bending modalities, particularly at the 12-month interval. This effect may be secondary to the limited surface area of device-vertebral endplate contact. Histomorphometric analysis of porous ingrowth coverage at the vertebral bone-metal interface was more favorable for total disc arthroplasty compared to historical reports of cementless femoral components. This project serves as the first comprehensive in vivo investigation into the AcroFlex disc prosthesis, and establishes an excellent research model in the evaluation of total disc replacement arthroplasty